ArticlePDF Available

Curcumin Therapy in Inflammatory Bowel Disease: A Pilot Study

Authors:

Abstract and Figures

Curcumin, a natural compound used as a food additive, has been shown to have anti-inflammatory and antioxidant properties in cell culture and animal studies. A pure curcumin preparation was administered in an open label study to five patients with ulcerative proctitis and five with Crohn's disease. All proctitis patients improved, with reductions in concomitant medications in four, and four of five Crohn's disease patients had lowered CDAI scores and sedimentation rates. This encouraging pilot study suggests the need for double-blind placebo-controlled follow-up studies.
Content may be subject to copyright.
Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005), pp. 2191–2193 (
C
2005)
DOI: 10.1007/s10620-005-3032-8
Curcumin Therapy in Inflammatory Bowel
Disease: A Pilot Study
PETER R. HOLT, MD,* SEYMOUR KATZ, MD, and ROBERT KIRSHOFF
Curcumin, a natural compound used as a food additive, has been shown to have anti-inflammatory
and antioxidant properties in cell culture and animal studies. A pure curcumin preparation was
administered in an open label study to five patients with ulcerative proctitis and five with Crohn’s
disease. All proctitis patients improved, with reductions in concomitant medications in four, and four
of five Crohn’s disease patients had lowered CDAI scores and sedimentation rates. This encouraging
pilot study suggests the need for double-blind placebo-controlled follow-up studies.
KEY WORDS: curcumin; ulcerative proctitis; Crohn’s disease; inflammatory bowel disease.
Curcumin is a natural compound found in the plant Cur-
cuma longa which is used as a food additive known as
turmeric. The major pigment in turmeric is curcumin
(chemical name diferuloymethane), which possesses both
anti-inflammatory (1, 2) and antioxidant properties (3, 4)
Topical application of curcumin inhibits carcinogen-
induced DMA adduct formation and the development of
skin tumors. Curcumin also strongly inhibits proliferation
of HT-29 and HCT-15 human colon cancer cell lines (5).
Dietary administration of curcumin suppresses the devel-
opment of chemically induced cancers. These properties
have led to studies of the chemopreventive effects of cur-
cumin which also showed that the agent reduces colonic
inflammatory responses (6). The background for such anti-
inflammatory activity rests in in vitro and animal model
studies. We report here our experience with curcumin ther-
apy in 10 patients with inflammatory bowel disease.
MATERIALS AND METHODS
Five consecutive patients with ulcerative proctitis or proc-
tosigmoiditis who agreed to participate in this study were en-
tered (Table 1). There were three women and two men, aged 28
Manuscript received March 21, 2004; accepted August 10, 2004.
From *St. Luke’s Roosevelt Hospital Center, Columbia University
and Strang Cancer Center Research Laboratory, New York, New York,
and Long Island Clinical Research Associates, Great Neck, New York,
USA.
Address for reprint requests: Peter R. Holt, MD,15 West 81 Street,
New York, New York 10024, USA; pholt@chpnet.org.
to 54 years, who had complained of proctitis symptoms for 1 to
32 years. All had been previously treated with 5-aminosalicyclic
acid (5ASA) compounds by mouth and/or rectum, three had re-
ceived corticosteroid therapy at some time, and one subject was
taking prednisone, 10 mg per day, at study entry.
They were treated with 550 mg of curcumin (DFM 100; 99.5%
pure
1
) twice daily for 1 month and then 550 mg three times daily
for another month. All had blood taken for hematologic and bio-
chemical analysis and for indexes of inflammation (sedimenta-
tion rate and C-reactive protein [CRP]) and had sigmoidoscopies
and biopsies both at baseline and 2 months later when the study
ended.
Symptoms were assessed by a standard questionnaire at the
start and conclusion of the study and by a daily symptom dairy.
The endoscopic evaluation was not blinded since the investigator
wasaware of the timing of the procedure, however, the biopsies
were obtained and evaluated for the degree of inflammation with-
out knowledge of their timing.
Five subjects, three men and two women, with an established
diagnosis of Crohn’s disease were entered in this pilot study to
determine whether the addition of curcumin to existing treat-
ments for Crohn’s disease would result in a reduction of in-
flammation with the ability to reduce other concomitant anti-
inflammatory agents (Table 1). The subjects were treated with
curcumin, 360 mg (1 capsule) three times daily for 1 month
and then 360 mg (4 capsules) four times daily for the remaining
2 months. Crohn’s Disease Activity Index (CDAI), CRP, ery-
throcyte sedimentation rate (ESR), complete blood counts, and
liver and renal function studies were obtained in all patients. All
patients signed a consent form and IRB permission was obtained
for this study.
1
Kindly provided by R. Kane Products, Pennsauken, New Jersey.
Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005)
2191
0163-2116/05/1100-2191/0
C
2005 Springer Science+Business Media, Inc.
HOLT ET AL.
T
ABLE 1. DATA ON ULCERATIVE PROCTOSIGMOIDITIS AND CROHNS DISEASE PATIENTS
Length of disease Medications at
Patient No. Age/sex Extent of disease history (yr) study entry
A. Ulcerative proctosigmoiditis
1. RK 52/F Proctitis 32 5ASA suppositories
Sulfasalazine, 2g 1d
2. EJ 30/F Proctitis 01 5ASA enemas and
suppositories
3. PM 28/M Proctitis 05 5ASA enemas
4. JM 29/M Proctitis 07 Sulfasalazine, 2g 1d
5ASA suppositories
5. RP 54/F Proctosigmoiditis 06 Prednisone, 10 mg
5ASA and enemas
Azathiopine, 100 mg
B. Crohn’s disease
1. JD 43/M lleocolitis 22 Colestid, 3/day
6MP, 75 mg
2. RK 47/M Crohn’s colitis 26 6MP, 75 mg
3. BE 65/F lleocolitis 11 6MP, 75 mg
4. JR 50/M lleojejunal colitis 23 Flagyl, 500 mg
Budesonide, 9 mg
5. JWP 33/F Ileitis 22 None
Note. 5ASA, 5-aminosalicylic acid; 6MP, 6-methylprednisone.
RESULTS
Overall, all five subjects with proctitis improved by the
end of the study as judged by a global score (P < 0.02;
Table 2). The major changes found were in the number and
quality of stools. Two subjects eliminated their prestudy
5ASA medications, two subjects reduced their medica-
tions (including termination of the prednisone therapy in
one subject), and one continued taking 5ASA supposito-
ries. In these patients with limited ulcerative colitis, sero-
logic indexes of inflammation, sedimentation rate, and
CRP returned to within normal limits at the conclusion
of the study.
The CDAI scores for all completed subjects fell, with
a mean reduction of 55 points; sedimentation rate fell
as well, with a mean reduction of 10 mm/hr (Table 3).
CRP was reduced by a mean of 0.1 mg/dl. There were no
changes in indexes of liver or renal function. Visits oc-
TABLE 2. EFFECTS OF CURCUMIN ADMINISTRATION IN ULCERATIVE PROCTITIS PATIENTS
General No. of Stool Stool Abdominal Rectal pain Global
Subject No. well-being stools quality blood pain urgency Medication Endoscopy score
1. Before 1 2–3 2 1 0 1 Eliminated 3 11
After 0 1 0 1 0 0 2 4
2. Before 1 4+ 13 02Unchanged 2 13
After 0 2–3 1 3 0 2 2 11
3. Before 0 2–3 1 0 0 0 Eliminated 0 4
After 0 1 0 0 0 0 0 1
4. Before 1 4+ 23 11Reduced++ 315
After 1 2–3 0 3 0 0 1 8
5. Before 4+ 1–2 1 0 1 Reduced 1 9
After 1–2 1–2 1 0 1 1 7
Note. Numbers represent semiquantitative scores ranging from 1 to 3. The higher the score, the worse the status.
curred every month, at which the four completed subjects
reported improvement in clinical symptoms as follows:
more formed stools, less frequent bowel movements, and
less abdominal pain and cramping. One subject reported
decreased muscle soreness, commonly felt after his exer-
cise routine. Of the five subjects, four successfully com-
pleted and one discontinued due to lack of treatment effect,
with a slight worsening of fistula output.
DISCUSSION
Curcumin has a profound immunosuppressive effect via
inhibition of IL-2 synthesis as well as IL-2 and mitogen
activation of human leukocytes. This immunosuppressive
effect may be mediated by NFκB inhibition (7).
Further support is offered by data indicating that cur-
cumin effectively inhibited tumor necrosis factor α and
2192 Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005)
CURCUMIN THERAPY IN INFLAMMATORY BOWEL DISEASE
T
ABLE 3. EFFECTS OF CURCUMIN ADMINISTRATION IN CROHNS
DISEASE PATIENTS
CDAI Sedimentation rate
Subject No. Index Change % change Rate Change % change
1. Before 225 23
After 196 29 12.9 19 4 17.4
2. Before 253 11
After 155 98 38.7 6 5 45.5
3. Before 250 24
After 239 11 44 7 17 70.8
4. Before 302 42
After 220 82 27.2 28 14 33.3
Note.CDAI, Crohn’s Disease Activity Index. Data for the four subjects
who completed the study.
phorbol ester-induced binding of NFκ B transcription
factors to sites located on the GSTP1-1 (glutathione
S-transferase P1-1) gene promoter. These results indi-
cate that curcumin could thereby induce apoptosis by its
ability to inhibit GSTP1-1 expression at the transcription
level (8).
In animal colitis models, curcumin has been shown to
attenuate or prevent DNB or trinitrobenzene sulfonic acid-
induced colitis in mice by suppressing CD4(+)T-cell in-
filtration and NHκ B activation as well as reducing p38
MAPX activity (9, 10). Based on these reports we have
shown that curcumin appears to have reduced the inflam-
matory response in four of five ulcerative colitis patients
and four of five Crohn’s disease patients.
Conclusion
The results of this pilot study indicate that further stud-
ies are warranted. A larger scale, double-blind, placebo-
controlled trial is indicated.
REFERENCES
1. Ammon HPT, Wahl M: Pharmacology of Curcuma longa. Planta
Med 57:1–7, 1991
2. Satoskar RR, Shah SJ, Shenoy SG: Evaluation of anti-inflammatory
property of curcumin (diferuloytmethane) in patients with postop-
erative inflammation. Int J Pharmacol Ther Toxicol 24:651–654,
1986
3. Surh YJ: Anti-tumor promoting potential of selected spice ingre-
dients with antioxidative and anti-inflammatory activities: a short
review. Food Chem Toxicol 40:1091–1097, 2002
4. Toda S, Miyase T, Aricht H, Tanizawa H, Takino Y: Natural antioxi-
dant HI antioxidative components isolated from rhizome of curcuma
longa. Chem Pharm Bull 33:1725–1728, 1985
5. Hanif R, Qiao L, Shiff SJ, Rigas B: Curcumin a natural
plant phenolic food additive inhibits cell proliferation and in-
duces ceil cycle changes in colon adenocarcinoma cell lines by
prostaglandin-independent pathways. J Lab Clin Med 130:576–584,
1997
6. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A,
Farrow S, Howells L: Inhibition of cyclo-oxygenase 2 expression
in colon cells by the chemopreventive agent curcumin involves in-
hibition of NF-κ B activation via the NIK/IKK signaling complex.
Oncogene 18:6013–6020, 1999
7. Ranjan D, Chen C, Johnston TO, Reddy KS, Khan TT, Nagabhushan
M: Curcumin inhibits mitogen stimulated lymphocyte prolifera-
tion NF-κ B activation and IL-2 signaling. J Surg Res 114:272,
2003
8. Duvoix A, Morceau F, Deihalle S, Schmitz M, Schnekenburger M,
Galteau MM, Dicato M, Diederichet M: Induction of apoptosis by
curcumin: mediation by giutathione S transferase P1-1 inhibition.
Biochem Pharmacol 66:1475–1483, 2003
9. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez-
Munoz A, Jacobsen K: Curcumin attenuates DNB-induced murine
colitis. Am J Physiol Gastrointest Liver Physiol 285:G235,
2003
10. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T,
Koide Y: Curcumin prevents and ameliorates trinitrobenzene sur-
fonic acide induced colitis in mice. Gastroenterology 123:1912–
1922, 2002
Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005)
2193
... In the same study, curcumin's efficacy as an add-on therapy to exis treatments of CD was also tested using 360 mg of curcumin three times a day for month, and then four times a day for two months, in five patients with CD. The Croh Disease Activity Index (CDAI) score and CRP levels for all subjects fell [49]. Another compared curcumin supplementation combined with either sulfasalazine or mesalam versus placebo in eighty-nine patients with quiescent UC. ...
... In the same study, curcumin's efficacy as an add-on therapy to existing treatments of CD was also tested using 360 mg of curcumin three times a day for one month, and then four times a day for two months, in five patients with CD. The Crohn's Disease Activity Index (CDAI) score and CRP levels for all subjects fell [49]. Another trial compared curcumin supplementation combined with either sulfasalazine or mesalamine versus placebo in eighty-nine patients with quiescent UC. ...
Article
Full-text available
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are a major healthcare challenge worldwide. Disturbances in the immune system and gut microbiota followed by environmental triggers are thought to be part of the aetiological factors. Current treatment for IBD includes corticosteroids, immunosuppressants, and other biologic agents; however, some patients are still unresponsive, and these are also linked to high financial load and severe side effects. Plant-derived natural products are rich in phytochemicals and have been used as healing agents in several diseases since antiquity due to their antioxidant, anti-inflammatory, and immunomodulatory properties, as well as gut microbiota modulation. Numerous in vitro and in vivo studies have shown that phytochemicals act in key pathways that are associated with the pathogenesis of IBD. It is also reported that the use of plant-derived natural products as complementary treatments is increasing amongst patients with IBD to avoid the side effects accompanying standard medical treatment. This review summarises the relevant evidence around the use of plant-derived natural products in the management of IBD, with specific focus on the clinical evidence so far for Curcumin, Mastiha, Boswellia serrata, and Artemisia absinthium.
... Indeed, effective chemopreventive medicines include anti-inflammatory drugs like sulindac and vitamin D3. Curcumin inhibits NF-κB and STAT3 signaling and has shown promise in treating Crohn's disease and familial adenomatous polyposis (FAP) [27,28] ...
... In addition, rhACE2 administration decreases AngII levels by acting on the nonclassical RAS pathway. This action lowers proinflammatory cytokine concentrations and improves prognosis in SARS-CoV-2 infection [27]. Overall, the use of rhACE2 can block early-stage SARS-CoV-2 infection and increase the effectiveness of remdesivir treatment when administered in combination. ...
Article
Full-text available
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is an emerging zoonotic virus, which causes Coronavirus Disease 2019 (COVID-19). Entry of coronaviruses into the cell depends on binding of the viral spike (S) proteins to cellular receptors Angiotensin-converting enzyme 2 (ACE2). The virus-mediated reduction of ACE2/Ang1-7 causes flooding of inflammatory cytokines. A similar scenario of hyper immunologic reaction has been witnessed in the context of Intestinal Inflammatory Diseases (IIDs) with the deregulation of ACE2. This review summarizes several IIDs that lead to such susceptible conditions. It discusses suitable mechanisms of how ACE2, being a crucial regulator of the Renin-Angiotensin System (RAS) signaling pathway, can affect the physiology of intestine as well as lungs, the primary site of SARS-CoV-2 infection. ACE2, as a SARS-CoV-2 receptor, establishes a critical link between COVID-19 and IIDs. Intercessional studies targeting the RAS signaling pathway in patients may provide a novel strategy for addressing the COVID-19 crisis. Hence, the modulation of these key RAS pathway members can be beneficial in both instances. However, it’s difficult to say how beneficial are the ACE inhibitors (ACEI)/ Angiotensin II type-1 receptor blockers (ARBs) during COVID-19. As a result, much more research is needed to better understand the relationship between the RAS and SARS-CoV-2 infection. Graphical Abstract
... Куркумин оказывает выраженное противовоспалительное действие (в моделях острого вос-паления столь же эффективен, как кортизон или фенилбутазон) [17,18], к его мишеням относятся факторы транскрипции (например, NF-κB), ферменты (например, циклооксигеназа-2, 5-липоксигеназа), провоспалительные цитокины (IL-1β, IL-6, IL-12, TNF-α, IFNγ) и связанные с ними сигнальные пути (AP-1, RANK/RANKL, JAK-STAT) [19]. Благодаря своим противовоспалительным свойствам куркумин используется при аутоиммунных заболеваниях, таких как ревматоидный артрит, воспалительные заболевания кишечника и рассеянный склероз [20]. ...
Article
Full-text available
The review presents an analysis of publications devoted to the identification of biological activity, component composition, pharmacological properties and therapeutic potential of various components of the Curcuma longa plant. This publication was prepared using mostly articles in PubMed, Scopus, and Web of Science. The analysis showed that Curcuma longa contains a wide range of biologically active substances, including curcuminoids, volatile oils, resins, alkaloids. Numerous in vivo and in vitro studies have demonstrated anti-inflammatory, antioxidant, antibacterial, antitumor, neuroprotective, antiproliferative and a number of other effects. Thus, Curcuma longa has a high therapeutic potential and can be a promising type of raw material for the development of drugs effective in various diseases.
... They found that the healing properties through in vivo studies indicated that the drugloaded PVA/sodium alginate composite nanofibers had the best performance. Curcumin, a natural polyphenol, can significantly improve symptoms in patients with colitis, and many studies have shown that curcumin has excellent anti-inflammatory, antioxidant, and antibacterial properties [42][43][44]. However, the in vivo bioavailability of curcumin is low due to relatively low absorption from the small intestine coupled with extensive reductive and conjugative metabolism in the liver and elimination through the gallbladder. ...
Article
Full-text available
Nanofibrous membranes made of hydrogels have high specific surface areas and are suitable as drug carriers. Multilayer membranes fabricated by continuous electrospinning could delay drug release by increasing diffusion pathways, which is beneficial for long-term wound care. In this experiment, polyvinyl alcohol (PVA) and gelatin were used as membrane substrates, and a sandwich PVA/gelatin/PVA structure of layer-by-layer membranes was prepared by electrospinning under different drug loading concentrations and spinning times. The outer layers on both sides were citric-acid-crosslinked PVA membranes loaded with gentamicin as an electrospinning solution, and the middle layer was a curcumin-loaded gelatin membrane for the study of release behavior, antibacterial activity, and biocompatibility. According to the in vitro release results, the multilayer membrane could release curcumin slowly; the release amount was about 55% less than that of the single layer within 4 days. Most of the prepared membranes showed no significant degradation during immersion, and the phosphonate-buffered saline absorption rate of the multilayer membrane was about five to six times its weight. The results of the antibacterial test showed that the multilayer membrane loaded with gentamicin had a good inhibitory effect on Staphylococcus aureus and Escherichia coli. In addition, the layer-by-layer assembled membrane was non-cytotoxic but detrimental to cell attachment at all gentamicin-carrying concentrations. This feature could be used as a wound dressing to reduce secondary damage to the wound when changing the dressing. This multilayer wound dressing could be applied to wounds in the future to reduce the risk of bacterial infection and help wounds heal.
... As reported in many papers (Ashraaf et al., 2023;Tyszkowski and Mehrzad, 2023), the potential roles of curcumin were explored against several inflammatory chronic ailments in humans. It was shown that curcumin exhibits considerable beneficial effects against Crohn's disease (Holt et al., 2005). ...
Article
Full-text available
Metabolic syndrome is one of the utmost frequent diseases with the augmentation of the fast oscillations in societies’ lifestyles. On the other side, various medicinal plants have recently been extensively used for plentiful therapeutics. Among these, curcumin and turmeric are the main components derivative from the rhizome of plants, with significant effects on preventing metabolic syndromes. Due to their antioxidant and anti-inflammatory activities, the biological activities of turmeric and its bioactive element, curcumin, have antidiabetic properties via augmenting insulin release and anti-hyperlipidemia effects via enhancing fatty acids uptake, anti-obesity properties via declining lipogenesis, and antihypertensive properties via augmenting nitric oxide synthesis. Moreover, the dietary presence of turmeric and its bioactive element, curcumin, significantly affected poultry productivity, health and welfare. According to human and animal trials, turmeric or curcumin has important values as dietary supplementation and complementary therapy in some metabolic syndromes. This scenario highpoint on the potential effects of curcumin (turmeric) on poultry health and its role in complementary therapy in metabolic syndrome. Additional high-quality clinical trial investigations are required to establish the clinical efficiency of the curcumin complement confidently.
Article
Budesonide (BUD), a locally acting glucocorticoid with low side effects, is recommended in several Crohn's disease (CD) drug treatment guidelines as the first choice for early treatment. Nevertheless, the extensive first-pass effect mediated by P-glycoprotein (P-gp) and Cytochrome P450 3A4 (CYP3A4) leads to low bioavailability and limits further applications. Curcumin (CUR), a natural polyphenol derived from turmeric, has been found to influence the in vivo processes of drugs by affecting the activity of P-gp and CYP3A4. However, the pharmacokinetic interactions between BUD and CUR remains elusive, so an ultra high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established for the simultaneous determination of BUD and CUR in the tissue. The results showed that the area under the concentration-time curve 0 to time (AUC0→t) of BUD in the colon and kidney increased by approximately 32.35% and 39.03% respectively in the co-administered group compared to the single-drug group, while the small intestine, liver and plasma decreased by 80.03%, 67.34% and 24.34% respectively compared to the single-drug group. Therefore, long-term treatment with CUR can increase the concentration of BUD in the colonic area without increasing its systemic exposure, thus potentially reducing the incidence of side effects.
Article
Curcumin, a natural polyphenol, derived from Curcuma longa L. is extensively studied by various researchers across the globe and has established its immense potential in the management of several disorders at clinical level. The underlying mechanism of curcumin involves regulation of various molecular targets, namely, inflammatory cytokines, transcription factor, apoptotic genes, growth factors, oxidative stress biomarkers, and protein kinases. In clinical trials, curcumin as an adjuvant has significantly boost‐up the efficacy of many proven drugs in the management of arthritis, neurodegenerative disorder, oral infection, and gastrointestinal disorders. Moreover, clinical studies have suggested curcumin as an appropriate candidate for the prevention and/or management of various cancers via regulation of signaling molecules including NF‐kB, cytokines, C‐reactive protein, prostaglandin E2, Nrf2, HO‐1, ALT, AST, kinases, and blood profiles. This article highlights plethora of clinical trials that have been conducted on curcumin and its derivatives in the management of several ailments. Besides, it provides recent updates to the investigators for conducting future research to fulfill the current gaps to expedite the curcumin utility in clinical subjects bearing different pathological states.
Article
Full-text available
Since the banning of antibiotics in animal feeds (2006), there has been an increase in the number of studies looking for alternatives to stimulate the gut immune system. The main objective of our review article is to underline the nutraceutical properties of Curcuma longa and Spirulina platensis in the broiler chicken industry, and the experimental data were obtained by analyzing literature sources. Spirulina platensis is widely recognized as a valuable protein source, containing approximately 55-70% protein, 25% carbohydrates, essential amino acids, and 18% fatty acids. It is also rich in various vitamins like thiamin, riboflavin, pyridoxine, vitamin B12, vitamin C, gamma-linolenic acid, phycocyanins, tocopherols, chlorophyll, beta-carotenes, carotenoids, exhibiting positive effects on growth performance, gut integrity, and immunity. The anti-inflammatory effect of spirulina supplementation at different levels showed a decrease in caspase-3 and the TNF-α immunolabeling index; a reduction in IL-1β, IL-2 and IFN-γ; and an increase in the expression of the anti-inflammatory cytokine IL-4. Spirulina inhibits the synthesis of cytokines IL-1, IL-6, and TNF-gamma in addition to the activities of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) enzymes. Turmeric also positively influences the growth, egg production, and overall health of chickens. Cur-cumin, the most potent component of turmeric, possesses additional pharmacological activities, including hepatoprotective, immunostimulant, and anticancer effects. Its immunomodulatory properties greatly enhance the immune system response, acting as a natural antibiotic against pathogens and decreasing levels of proinflammatory interleukins IL-1β, IL-6, IL-2, IL-18, and TNF-α.
Article
Full-text available
Colorectal cancer is a major cause of cancer deaths in Western countries, but epidemiological data suggest that dietary modification might reduce these by as much as 90%. Cyclo-oxygenase 2 (COX2), an inducible isoform of prostaglandin H synthase, which mediates prostaglandin synthesis during inflammation, and which is selectively overexpressed in colon tumours, is thought to play an important role in colon carcinogenesis. Curcumin, a constituent of turmeric, possesses potent anti-inflammatory activity and prevents colon cancer in animal models. However, its mechanism of action is not fully understood. We found that in human colon epithelial cells, curcumin inhibits COX2 induction by the colon tumour promoters, tumour necrosis factor alpha or fecapentaene-12. Induction of COX2 by inflammatory cytokines or hypoxia-induced oxidative stress can be mediated by nuclear factor kappa B (NF-kappaB). Since curcumin inhibits NF-kappaB activation, we examined whether its chemopreventive activity is related to modulation of the signalling pathway which regulates the stability of the NF-kappaB-sequestering protein, IkappaB. Recently components of this pathway, NF-kappaB-inducing kinase and IkappaB kinases, IKKalpha and beta, which phosphorylate IkappaB to release NF-kappaB, have been characterised. Curcumin prevents phosphorylation of IkappaB by inhibiting the activity of the IKKs. This property, together with a long history of consumption without adverse health effects, makes curcumin an important candidate for consideration in colon cancer prevention.
Article
Full-text available
Numerous therapies used for inflammatory bowel disease (IBD) target the transcription factor NF-kappaB, which is involved in the production of cytokines and chemokines integral for inflammation. Here we show that curcumin, a component of the spice turmeric, is able to attenuate colitis in the dinitrobenzene sulfonic acid (DNB)-induced murine model of colitis. When given before the induction of colitis it reduced macroscopic damage scores and NF-kappaB activation. This was accompanied by a reduction in myeloperoxidase activity, and using semiquantitative RT-PCR, an attenuation of the DNB-induced message for IL-1beta was detected. Western blotting analysis revealed that there was a reproducible DNB-induced activation of p38 MAPK detected in intestinal lysates by using a phosphospecific antibody. This signal was significantly attenuated by curcumin. Furthermore, we show that the immunohistochemical signal is dramatically attenuated at the level of the mucosa by curcumin. We conclude that the widely used food additive curcumin is able to attenuate experimental colitis through a mechanism correlated with the inhibition of the activation of NF-kappaB and effects a reduction in the activity of p38 MAPK. We propose that this agent may have therapeutic implications for human IBD.
Article
Background: T cell mediated acute rejection of transplanted organ continues to be a significant problem in solid organ transplantation. We had shown that curcumin is a potent inhibitor of Cyclosporin A resistant T cell CD28 co-stimulation pathway. Here we report the inhibitory effects of curcumin on mitogen stimulated lymphocyte proliferation, IL-2 synthesis/ signaling and on NFκB (component of IL2 promoter gene) activation . Methods: Human lymphocytes were isolated from fresh human spleen (SP-L). Mitogens [final concentrations of 2 μg/ml of concanavalin A (Con A), 5 μg/ml of phytohemagglutinin (PHA) and 20 ng/ml of phorbol-12-myristate 13-acetate (PMA)] were added to the designated wells in 96 well plate with 0.2 million SP and cultured for 48 h and then assayed for IL-2 synthesis by ELISA and 3H-thymidine uptake. In another parallel experiment we added IL-2 (0.5 nM) to stimulate the cells to bypass curcumin’s inhibition of IL-2 synthesis as the sole reason for inhibition of proliferation. Electrophorectic magnetic shift assay (EMSA) was performed in PMA (20 ng/ml,1 h) stimulated cells with or without curcumin to assay NFκB activation. Results: Curcumin at 2.5 μg/ml inhibited Con A, PHA and PMA stimulated SP-L proliferation at 77%, 23% and 48% respectively over controls and curcumin at 5 μg/ml completely (nearly 100%) inhibited the mitogen stimulated proliferation. Curcumin inhibited IL-2 synthesis in Con A, PHA and PMA stimulated SP-L in a concentration dependent manner with an ED50 (concentration required for 50% inhibition) measured at 3.5 μg/ml. Exogenous IL-2 stimulated SP-L proliferation was also inhibited by curcumin in a concentration dependent manner with an ED50 of 2 μg/ml. EMSA assay indicated that PMA at 20 ng/ml stimulated NFκB activation 253% over control which was inhibited by 24%, 38% and 73% respectively with curcumin at final concentrations of 2.5, 5 and 10 μg/ml respectively. Conclusion: Curcumin has profound immunosuppressive effects mediated via inhibition of IL-2 synthesis, mitogen and IL-2 induced activation of human lymphocytes. This effect may be mediated via NFκB inhibition.
Article
The data reviewed indicate that extracts of Curcuma longa exhibit anti-inflammatory activity after parenteral application in standard animal models used for testing anti-inflammatory activity. It turned out that curcumin and the volatile oil are at least in part responsible for this action. It appears that when given orally, curcumin is far less active than after i.p. administration. This may be due to poor absorption, as discussed. Data on histamine-induced ulcers are controversial, and studies on the secretory activity (HCl, pepsinogen) are still lacking. In vitro, curcumin exhibited antispasmodic activity. Since there was a protective effect of extracts of Curcuma longa on the liver and a stimulation of bile secretion in animals, Curcuma longa has been advocated for use in liver disorders. Evidence for an effect on liver disease in humans is not yet available. From the facts that after oral application only traces of curcumin were found in the blood and that, on the other hand, most of the curcumin is excreted via the faeces it may be concluded that curcumin is absorbed poorly by the gastrointestinal tract and/or underlies pre-systemic transformation. Systemic effects therefore seem to be questionable after oral application except that they occur at very low concentrations of curcumin. This does not exclude a local action in the gastrointestinal tract.
A new model for evaluating nonsteroidal anti-inflammatory drugs (NSAIDs) is described. In this model of postoperative inflammation, the anti-inflammatory activity of curcumin (diferuloyl methane) was investigated in comparison with phenylbutazone and placebo. Phenylbutazone and curcumin produced a better anti-inflammatory response than placebo.
Article
Antioxidative components in the methanol extract of the rhizome of Curcuma longa L. were investigated by using our evaluation method based on the air oxidation of linoleic acid. Curcuminoids such as curcumin, 4-hydroxycinnamoyl (feruloyl) methane and bis (4-hydroxycinnamoyl) methane were found to be active components. Curcumin was the most active component and its 50% inhibitory concentrations for the air oxidation of linoleic acid were 1.83×10-2% (thiobarbituric acid value) and 1.15×10-2% (peroxide value). These values of curcumin are superior to those of dl-α-tocopherol.
Article
Curcumin, the active ingredient of the rhizome of the plant turmeric (Curcuma longa Linn), a commonly used spice, prevents cancer in animal tumor models. Its mechanism of action is unknown; curcumin may act by inhibiting arachidonic acid metabolism. To explore the mechanism of curcumin's chemopreventive effect, we studied its role in proliferation and apoptosis in the HT-29 and HCT-15 human colon cancer cell lines. Curcumin dose-dependently reduced the proliferation rate of both cell lines, causing a 96% decrease by 48 hours. No apoptosis was detected. The antiproliferative effect was preceded by accumulation of the cells in the G2/M phase of cell cycle. The effect of curcumin was similar in both cell lines, which, however, differ in their ability to produce prostaglandins. We conclude that curcumin inhibits colon cancer cell proliferation in vitro mainly by accumulating cells in the G2/M phase and that this effect is independent of its ability to inhibit prostaglandin synthesis. The role of curcumin's antiproliferative effect in human colon cancer remains to be established.
Article
A wide variety of phenolic substances derived from spice possess potent antimutagenic and anticarcinogenic activities. Examples are curcumin, a yellow colouring agent, contained in turmeric (Curcuma longa L., Zingiberaceae), [6]-gingerol, a pungent ingredient present in ginger (Zingiber officinale Roscoe, Zingiberaceae) and capsaicin, a principal pungent principle of hot chili pepper (Capsicum annuum L, Solanaceae). The chemopreventive effects exerted by these phytochemicals are often associated with their antioxidative and anti-inflammatory activities. Cyclo-oxygenase-2 (COX-2) has been recognized as a molecular target of many chemopreventive as well as anti-inflammatory agents. Recent studies have shown that COX-2 is regulated by the eukaryotic transcription factor NF-kappaB. This short review summarizes the molecular mechanisms underlying chemopreventive effects of the aforementioned spice ingredients in terms of their effects on intracellular signaling cascades, particularly those involving NF-kappaB and mitogen-activated protein kinases.
Article
Expression of glutathione S-transferase P1-1 (GSTP1-1) is correlated to carcinogenesis and resistance of cancer cells against chemotherapeutic agents. Curcumin, a natural compound extracted from Curcuma longa, has shown strong antioxidant and anticancer properties and also the ability to regulate a wide variety of genes that require activating protein 1 and nuclear factor kappaB (NF-kappaB) activation. In the present study, we examined the inhibitory effect of curcumin on the expression of GSTP1-1 mRNA as well as protein, and we correlated this inhibition with the apoptotic effect of curcumin on K562 leukemia cells. Curcumin efficiently inhibited the tumour necrosis factor alpha- and phorbol ester-induced binding of AP-1 and NF-kappaB transcription factors to sites located on the GSTP1-1 gene promoter. TNFalpha-induced GSTP1-1 promoter activity was also inhibited by curcumin as shown by reporter gene assay. In parallel, curcumin induced pro-caspases 8 and 9 as well as poly ADP ribose polymerase cleavage and thus leading to apoptosis in K562 cells. Our results overall add a novel role for curcumin as this chemoprotective compound could contribute to induce apoptosis by its ability to inhibit the GSTP1-1 expression at the level of transcription.
Article
T cell mediated acute rejection of transplanted organ continues to be a noticeable problem in solid organ transplantation. We showed that Curcumin is a potent inhibitor of Cyclosporin A resistant T cell CD28 co-stimulation pathway. Here we report the inhibitory effects of Curcumin on mitogen-stimulated lymphocyte proliferation, IL-2 synthesis/signaling, and NFkappaB (transcription factor of IL-2 promoter) activation. Human lymphocytes were isolated from fresh human spleen (SP-L). Mitogens [final concentrations of 2 microg/ml concanavalin A (Con A), 5 microg/ml phytohemagglutinin (PHA), and 20 ng/ml of phorbol-12-myristate-13-acetate (PMA)] were added to the designated wells in a 96-well plate with 0.2 million SP-L and cultured for 48 h and then assayed for IL-2 synthesis by ELISA and 3H-thymidine uptake. In another parallel experiment we added IL-2 (0.5 nM) to stimulate the cells to check if Curcumin's inhibition of IL-2 synthesis is the sole reason for inhibition of cell proliferation. Electrophoretic mobility shift assay (EMSA) was performed in PMA (20 ng/ml, 1 h) stimulated cells with or without Curcumin to assay NFkappaB activation. Curcumin at 2.5 microg/ml inhibited Con A, PHA, and PMA stimulated SP-L proliferation at 77, 23, and 48%, respectively, over controls and Curcumin at 5 microg/ml completely (nearly 100%) inhibited the mitogen stimulated proliferation. Curcumin inhibited IL-2 synthesis in Con A, PHA, and PMA stimulated SP-L in a concentration-dependent manner with an ED50 (concentration required for 50% inhibition) measured at 3.5 microg/ml. Exogenous IL-2 stimulated SP-L proliferation was also inhibited by Curcumin in a concentration-dependent manner with an ED50 of 2 microg/ml. EMSA assay indicated that PMA at 20 ng/ml stimulated NFkappaB activation 253% over control, which was inhibited by 24, 38, and 73%, respectively, with Curcumin at final concentrations of 2.5, 5, and 10 microg/ml, respectively. Curcumin has profound immunosuppressive effects mediated via inhibition of IL-2 synthesis, mitogen, and IL-2 induced activation of human lymphocytes. This effect may be mediated via NFkappaB inhibition.